A. V. Lee

Estrogen regulation and functional role of FGFR4 in estrogen receptor positive breast cancer

This study investigates FGFR4's role in endocrine resistance in ER+ breast cancer and finds it does not generally mediate resistance, though HER2-like subtypes may respond to FGFR4 inhibition.

mDia2 is an important mediator of MRTF-A-dependent regulation of breast cancer cell migration

This study identifies mDia2 as a mediator of MRTF-A-dependent breast cancer cell migration and links MRTF activity to malignancy, suggesting it as a therapeutic target.

Breast cancer cells promote osteoclast differentiation in an MRTF-dependent paracrine manner

This study shows that MRTF in breast cancer cells promotes osteoclast differentiation via paracrine signaling, enhancing bone metastasis, and suggests MRTF inhibition as a potential therapeutic strategy.

Multi-omic characterization of ILC and ILC-like cell lines as part of ILC cell line encyclopedia (ICLE) defines new models to study potential biomarkers and explore therapeutic opportunities

The paper characterizes ILC and ILC-like cell lines through multi-omic analysis to identify molecular similarities with patient tumors and potential therapeutic targets.

ESR1 fusion proteins invoke breast cancer subtype-dependent enrichment of ligand independent pro-oncogenic signatures and phenotypes

This study shows ER fusion proteins in breast cancer cell lines drive ligand-independent pro-oncogenic pathways, with subtype- and fusion-specific effects.

Spatial molecular profiling of mixed invasive ductal-lobular breast cancers reveals heterogeneity in intrinsic molecular subtypes, oncogenic signatures, and mutations

This study uses spatial molecular profiling to show that mixed invasive ductal-lobular breast cancers have distinct molecular subtypes, oncogenic signatures, and mutations in different tumor regions, leading to prognostic uncertainty and therapeutic challenges.

Small molecule nitroalkenes inhibit RAD51-mediated homologous recombination and amplify triple-negative breast cancer cell killing by DNA-directed therapies.

This paper identifies nitroalkenes that inhibit RAD51-mediated homologous recombination, enhancing DNA damage in triple-negative breast cancer cells and showing potential as anticancer agents.

EstroGene database reveals diverse temporal, context-dependent and directional estrogen receptor regulomes in breast cancer

The paper establishes the EstroGene database, which compiles 246 experiments from 136 datasets to analyze estrogen receptor regulomes in breast cancer, revealing diverse temporal, context-dependent, and directional responses.

Loss of E-cadherin Induces IGF1R Activation Revealing a Targetable Pathway in Invasive Lobular Breast Carcinoma

This study shows that loss of E-cadherin in ILC leads to increased IGF1R activation and sensitivity to inhibitors, suggesting a therapeutic target and biomarker for ILC.

Hotspot ESR1 mutations are multimodal and contextual drivers of breast cancer metastasis

This study identifies ESR1 mutations as drivers of breast cancer metastasis by altering cell adhesion and migration through genomic and transcriptomic reprogramming.

ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation

This study shows ESR1 mutant breast cancers exhibit basal cytokeratin expression and immune activation, linked to chromatin reprogramming and paracrine signaling.

Salicylate, Bile Acids and Extreme Acid Cause Fitness Tradeoffs for Multidrug Pumps in Escherichia coli K-12

This study investigates how salicylate, bile acids, and extreme acid affect the fitness of multidrug efflux pumps in E. coli, revealing tradeoffs and conditions under which these pumps confer advantages or costs.

Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrences

This study analyzes acquired mutations and transcriptional changes in long-term estrogen-deprived breast cancer recurrences, identifying common genetic and expression alterations associated with endocrine resistance.

Single cell transcriptomic heterogeneity in invasive ductal and lobular breast cancer cells

The paper uses single-cell RNA sequencing to compare transcriptional heterogeneity between invasive ductal and lobular breast cancer cell lines, identifying CDH1 loss effects and potential mediators of ILC-specific features.

A negative feedback loop between Insulin-like Growth Factor signaling and the lncRNA SNHG7 tightly regulates transcript levels and proliferation

The paper shows IGF1 signaling down-regulates SNHG7, a lncRNA that promotes breast cancer cell proliferation and modulates IGF1 signaling through a feedback mechanism, with SNHG7 overexpression linked to poor patient outcomes.

Proteomic and Transcriptomic Profiling Identifies Mediators of Anchorage-Independent Growth and Roles of Inhibitor of Differentiation Proteins in Invasive Lobular Breast Cancer

The paper identifies ID1 and ID3 as novel drivers of anchorage-independent growth in invasive lobular breast cancer through proteomic and transcriptomic profiling.

Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors

The paper compares immune cell infiltration in primary and metastatic breast tumors, finding reduced immune cell abundance but increased M2-like macrophages in metastases.

Targeted mutation detection in breast cancer using MammaSeqTM

The paper develops MammaSeq, a targeted NGS panel for detecting clinically actionable mutations in breast cancer, showing it identifies actionable variants in 48% of solid tumors and 29% of cfDNA samples.

Loss of E-cadherin enhances IGF1-IGF1R pathway activation and sensitizes breast cancers to anti-IGF1R inhibitors

This study shows that loss of E-cadherin increases IGF1R pathway activation and makes breast cancers more responsive to anti-IGF1R therapies.

Exome-Capture RNA-Sequencing Of Decade-Old Breast Cancers And Matched Decalcified Bone Metastases Identifies Clinically Actionable Targets

This study uses exome-capture RNA-sequencing on decade-old breast cancer specimens and matched bone metastases to identify clinically actionable gene expression changes in metastatic progression.